Can the careHPV test performed in mobile units replace cytology for screening in rural and remote areas?

Cancer Cytopathology

Volumn 124, Issue 8, 2016, Pages 581-588

  Lorenzi, Adriana T ^a   Fregnani, José Humberto T ^a   Possati Resende, Júlio César ^a   Antoniazzi, Márcio ^a   Scapulatempo Neto, Cristovam ^a   Syrjänen, Stina ^b,c   Villa, Luisa L ^d,e   Longatto Filho, Adhemar ^a,e,f  

^a BARRETOS CANCER HOSPITAL   (Brazil)

^b UNIVERSITY OF TURKU   (Finland)

^c TURKU UNIVERSITY HOSPITAL   (Finland)

^d FACULDADE DE CIÊNCIAS MÉDICAS DA SANTA CASA DE SÃO PAULO   (Brazil)

^e UNIVERSITY OF SÃO PAULO   (Brazil)

^f UNIVERSITY OF MINHO   (Portugal)

Author keywords

cancer screening; cervical cancer; colposcopy; human papillomavirus (HPV) DNA tests; Papanicolaou test

Indexed keywords

ADULT; AGED; ARTICLE; BRAZIL; CANCER GRADING; CANCER SCREENING; COLPOSCOPY; CYTOLOGY; FEMALE; HEALTH CARE FACILITY; HEALTH CARE PERSONNEL; HIGH RISK PATIENT; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; MOBILE APPLICATION; MOBILE UNIT; PAPANICOLAOU TEST; PRIORITY JOURNAL; PROCESS DEVELOPMENT; RURAL AREA; SQUAMOUS CELL; SQUAMOUS INTRAEPITHELIAL LESION OF THE CERVIX; UTERINE CERVIX CANCER;

EID: 84982135194     PISSN: 1934662X     EISSN: 19346638     Source Type: Journal    
DOI: 10.1002/cncy.21718     Document Type: Article

References (50)

1. World Health Organization and International Agency for Research on Cancer. Cervical cancer-estimated incidence, mortality and prevalence worldwide in 2012. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. Accessed January 20, 2015.
2. Instituto Nacional do Cancer/National Cancer Institute (INCA). Cancer in Brazil: data from population-based records [in Portuguese]. http://www.inca.gov.br/estimativa/2016/.
3. Forman D, de Martel C, Lacey CJ, et al. Global burden of human papillomavirus and related diseases. Vaccine. 2012;30(suppl 5):F12-F23.
4. Doorbar J, Quint W, Banks L, et al. The biology and life-cycle of human papillomaviruses. Vaccine. 2012;30(suppl 5):F55-F70.
5. Zhao FH, Tiggelaar SM, Hu SY, et al. A multi-center survey of age of sexual debut and sexual behavior in Chinese women: suggestions for optimal age of human papillomavirus vaccination in China. Cancer Epidemiol. 2012;36:384-390.
6. Rositch AF, Koshiol J, Hudgens MG, et al. Patterns of persistent genital human papillomavirus infection among women worldwide: a literature review and meta-analysis. Int J Cancer. 2013;133:1271-1285.
7. Arbyn M, Ronco G, Anttila A, et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine. 2012;30(suppl 5):F88-F99.
8. Paengchit K, Kietpeerakool C, Wangchai W, Pouraeng S, Lalitwongsa S. Cervical pathology in cytology-negative/HPV-positive women: results from Lampang Cancer Hospital, Thailand. Asian Pac J Cancer Prev. 2014;15:7951-7954.
9. Saslow D, Solomon D, Lawson HW, et al; ACS-ASCCP-ASCP Cervical Cancer Guideline Committee. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin. 2012;62:147-172.
10. Schiffman M, Burk RD, Boyle S, et al. A study of genotyping for management of human papillomavirus-positive, cytology-negative cervical screening results. J Clin Microbiol. 2015;53:52-59.
11. Castle PE, Glass AG, Rush BB, et al. Clinical human papillomavirus detection forecasts cervical cancer risk in women over 18 years of follow-up. J Clin Oncol. 2012;30:3044-3050.
12. Lin CQ, Chen F, Liu B, et al. A parallel study of careHPV and Hybrid Capture 2 human papillomavirus DNA testing for cervical cancer screening in rural China. J Virol Methods. 2014;202:73-78.
13. Qiao YL, Sellors JW, Eder PS, et al. A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. Lancet Oncol. 2008;9:929-936.
14. Qiagen. The careHPV Test Training Guide. Gaithersburg, MD: Qiagen; 2008.
15. Moyer VA; US Preventive Services Task Force. Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;156:880-891, W312.
16. Castle PE, de Sanjose S, Qiao YL, Belinson JL, Lazcano-Ponce E, Kinney W. Introduction of human papillomavirus DNA screening in the world: 15 years of experience. Vaccine. 2012;30(suppl 5):F117-F122.
17. Jeronimo J, Bansil P, Valdez M, et al. The influence of human papillomavirus genotypes on visual screening and diagnosis of cervical precancer and cancer. J Low Genit Tract Dis. 2015;19:220-223.
18. Campos NG, Burger EA, Sy S, et al. An updated natural history model of cervical cancer: derivation of model parameters. Am J Epidemiol. 2014;180:545-555.
19. Lorenzi AT, Fregnani JH, Possati-Resende JC, Neto CS, Villa LL, Longatto-Filho A. Self-collection for high-risk HPV detection in Brazilian women using the careHPV™ test. Gynecol Oncol. 2013;131:131-134.
20. Poljak M, Cuzick J, Kocjan BJ, Iftner T, Dillner J, Arbyn M. Nucleic acid tests for the detection of alpha human papillomaviruses. Vaccine. 2012;30(suppl 5):F100-F106.
21. Qiao YL, Jeronimo J, Zhao FH, et al. Lower cost strategies for triage of human papillomavirus DNA-positive women. Int J Cancer. 2014;134:2891-2901.
22. Zhao FH, Jeronimo J, Qiao YL, et al. An evaluation of novel, lower-cost molecular screening tests for human papillomavirus in rural China. Cancer Prev Res (Phila). 2013;6:938-948.
23. Chen W, Jeronimo J, Zhao FH, et al. The concordance of HPV DNA detection by Hybrid Capture 2 and careHPV on clinician- and self-collected specimens. J Clin Virol. 2014;61:553-557.
24. Kang LN, Jeronimo J, Qiao YL, et al. Optimal positive cutoff points for careHPV testing of clinician- and self-collected specimens in primary cervical cancer screening: an analysis from rural China. J Clin Microbiol. 2014;52:1954-1961.
25. de Aguiar SR, Villanova FE, Martins LC, et al. Human papillomavirus: prevalence and factors associated in women prisoners population from the Eastern Brazilian Amazon. J Med Virol. 2014;86:1528-1533.
26. Rosa MI, Fachel JM, Rosa DD, Medeiros LR, Igansi CN, Bozzetti MC. Persistence and clearance of human papillomavirus infection: a prospective cohort study. Am J Obstet Gynecol. 2008;199:617.e1–7.
27. Nonnenmacher B, Breitenbach V, Villa LL, Prolla JC, Bozzetti MC. Genital human papillomavirus infection identification by molecular biology among asymptomatic women [in Portuguese]. Rev Saude Publica. 2002;36:95-100.
28. Ayres AR, Silva GA. Cervical HPV infection in Brazil: systematic review [Article in English, Portuguese]. Rev Saude Publica. 2010;44:963-974.
29. de Sanjose S, Diaz M, Castellsague X, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis. 2007;7:453-459.
30. Fernandes JV, Meissner Rde V, de Carvalho MG, Fernandes TA, de Azevedo PR, Villa LL. Prevalence of HPV infection by cervical cytologic status in Brazil. Int J Gynaecol Obstet. 2009;105:21-24.
31. Katki HA, Schiffman M, Castle PE, et al. Five-year risks of CIN 3+ and cervical cancer among women who test Pap-negative but are HPV-positive. J Low Genit Tract Dis. 2013;17(5 suppl 1):S56-S63.
32. Katki HA, Schiffman M, Castle PE, et al. Five-year risks of CIN 3+ and cervical cancer among women with HPV testing of ASC-US Pap results. J Low Genit Tract Dis. 2013;17(5 suppl 1):S36-S42.
33. Labani S, Asthana S. Human papillomavirus viral load on careHPV testing of self-collected vaginal samples vs. clinician-collected cervical samples. Eur J Obstet Gynecol Reprod Biol. 2014;181:233-239.
34. Schmitt FC, Longatto-Filho A, Valent A, Vielh P. Molecular techniques in cytopathology practice. J Clin Pathol. 2008;61:258-267.
35. Labani S, Asthana S. Age-specific performance of careHPV versus Papanicolaou and visual inspection of cervix with acetic acid testing in a primary cervical cancer screening. J Epidemiol Community Health. 2016;70:72-77.
36. Zhao FH, Lewkowitz AK, Chen F, et al. Pooled analysis of a self-sampling HPV DNA test as a cervical cancer primary screening method. J Natl Cancer Inst. 2012;104:178-188.
37. Mayrand MH, Duarte-Franco E, Rodrigues I, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med. 2007;357:1579-1588.
38. Gage JC, Katki HA, Schiffman M, et al. The low risk of precancer after a screening result of human papillomavirus-negative/atypical squamous cells of undetermined significance Papanicolaou and implications for clinical management. Cancer (Cancer Cytopathol). 2014;122:842-850.
39. World Health Organization. Comprehensive Cervical Cancer Control-A Guide to Essential Practice. Geneva, Switzerland: World Health Organization; 2014.
40. Becker E, Edelweiss MI, Nonnenmacher B, Bozzetti MC. Prevalence and epidemiologic correlates of atypical squamous cells of undetermined significance in women at low risk for cervical cancer. Diagn Cytopathol. 2001;24:276-282.
41. Noronha VL, Cruz EM, Pinho CN, Mello WA, Villa LL, Russomano FB. Papilomavírus Humano (HPV) em Mulheres Submetidas a Rastreamento para Câncer de Cérvice Uterina, Belém – Pará – Brasil [in Portuguese]. J Bras Doenças Sex Transm. 2011;23:5-11. doi: 10.5533/2177-8264-201123103.
42. Entiauspe LG, Silveira M, Nunes EM, et al. High incidence of oncogenic HPV genotypes found in women from Southern Brazil. Braz J Microbiol. 2014;45:689-694.
43. Longatto-Filho A, Schmitt FC. Gynecological cytology: too old to be a pop star but too young to die. Diagn Cytopathol. 2007;35:672-673.
44. Dijkstra MG, van Niekerk D, Rijkaart DC, et al. Primary hrHPV DNA testing in cervical cancer screening: how to manage screen-positive women? A POBASCAM trial substudy. Cancer Epidemiol Biomarkers Prev. 2014;23:55-63.
45. Saayman F, Van Gelderen CJ, Michelow P, Van Den Berg EJ, Adam Y. Effect of 2 referral intervals on diagnostic discordance between cytology and histology at a colposcopy clinic. Int J Gynaecol Obstet. 2013;120:257-261.
46. Diaz ML. Counseling the patient with HPV disease. Obstet Gynecol Clin North Am. 2013;40:391-402.
47. Tahseen S, Reid PC. Psychological distress associated with colposcopy: patients' perception. Eur J Obstet Gynecol Reprod Biol. 2008;139:90-94.
48. Fakokunde B, Selo-Ojeme D. Impact of prolonged referral interval on colposcopic outcomes in women with moderate or severe dysplasia. Int J Gynaecol Obstet. 2008;101:245-247.
49. Sankaranarayanan R, Nene BM, Shastri SS, et al. HPV screening for cervical cancer in rural India. N Engl J Med. 2009;360:1385-1394.
50. Louvanto K, Chevarie-Davis M, Ramanakumar AV, Franco EL, Ferenczy A. HPV testing with cytology triage for cervical cancer screening in routine practice. Am J Obstet Gynecol. 2014;210:474.e1–7.